Researchers identify new way to inhibit immune cells that drive allergic asthma

Researchers at USC have discovered that activating the Piezo1 protein reduces inflammation caused by immune cells in the lungs in response to allergens. ILC2s, a type of immune cell, play a crucial role in allergic asthma by driving inflammation in the lungs, leading to airway tightening. Activation of Piezo1 channels by a drug called Yoda1 reduces ILC2 activity, inflammation, and asthma symptoms in mice. Human ILC2s also produce Piezo1, indicating the potential for Yoda1 as a therapeutic tool for allergic asthma. Future studies will focus on developing Piezo1-driven therapeutics for treating asthma in humans.

Source link

error: Content is protected !!